Page last updated: 2024-11-04

dibenzylchlorethamine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Dibenzylchlorethamine: An alpha adrenergic antagonist. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5820
CHEMBL ID3305685
SCHEMBL ID479112
MeSH IDM0454899

Synonyms (46)

Synonym
AA-516/31407024
n,n-dibenzyl-n-(2-chloroethyl)amine
dibenzyl-2-chloroethylamine
2-chloroethyldibenzylamine
n,n-dibenzyl-beta-chloroethylamine
dibenzyl chlorethylamine
dibenzyl(2-chloroethyl)amine
skf 199
n-(2-chloroethyl)dibenzylamine
dibenzylchlorethamine
dibenzylamine, n-(2-chloroethyl)-
2-(dibenzylamino)ethyl chloride
hsdb 2086
n,n-dibenzyl-2-chloroethylamine
dibenamine
benzenemethanamine, n-(2-chloroethyl)-n-(phenylmethyl)-
brn 2213696
dibenzylchlorethylamine
PDSP2_001084
PDSP1_001100
n,n-dibenzyl-2-chloroethanamine
bdbm81445
nsc_5820
cas_55-43-6
AKOS005459848
51-50-3
unii-43exu2s56h
43exu2s56h ,
4-12-00-02180 (beilstein handbook reference)
STK526670
BBL028457
1-dibenzylamino-2-chloroethane
dibenzyl-(2-chloro-ethyl)-amine
dibenamine [mi]
n,n-dibenzyl-.beta.-chloroethylamine
n,n-dibenzylaminoethyl chloride
n-(2-chloroethyl)-n-(phenylmethyl)benzenemethanamine
dibenamine [hsdb]
SCHEMBL479112
CHEMBL3305685
n,n-dibenzyl-2-chloroethanamine #
DTXSID20199001
sr-01000883996
SR-01000883996-1
2-chloro-n,n-bis(phenylmethyl)ethanamine
Q27258645

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" (2) The dose-response curves for the relaxation by ISO shifted to the right in a parallel manner as the concentration of the spasmogen increased, and became stationary at high concentrations of the spasmogen."( Studies on the mode of antagonism between adrenergic beta-mimetics and beta-blocking agents (III). Functional antagonism between beta-mimetics and spasmogens.
Ohashi, M, 1976
)
0.26
" From dose-response curves for adrenaline and 5-hydroxytryptamine (5-HT) obtained in strips of rat aorta before and after incubation with each of the three blocking agents, the fractions of receptors remaining active for adrenaline and 5-HT, respectively, were estimated."( Selective alpha-adrenoceptor blocking actions of a new derivative of 2-halogenotheylamine: 6-(2-bromoethyl)-10,11-methylenedioxy-5,6,7,8-tetrahydrodibenz[c,e]azocine.
Ishida, Y; Kihar, M; Kobayashi, S; Watanabe, K, 1976
)
0.26
" The dose-response curves were carefully checked in each experiment to confirm that the second protectors did not interfere with the specific coverage provided by the first protector."( Purification of histamine receptor (VI). An improved double labeling method with "double protection".
Uchida, M, 1977
)
0.26
" The dose-response curves generated by the model for partial agonists were similar to the curves obtained experimentally in vitro."( Relationship between alpha-adrenoceptor occupancy and contractile response in rat vas deferens. Experimental and theoretical analysis.
Díaz-Toledo, A; Martí, MC, 1988
)
0.27
"Two beta-carbolines, methyl beta-carboline-3-carboxylate (beta-CCM) and ethyl beta-carboline-3-carboxylate (beta-CCE), caused the parallel shift of the dose-response curve for cholecystokinin (CCK) in isolated guinea-pig gallbladder muscle."( Beta-carbolines selectively antagonize the cholecystokinin action in isolated guinea-pig gallbladder muscle.
Itonaga, M; Kubota, K, 1986
)
0.27
" When isolated longitudinal muscle strips from this preparation were tested with E-2-P before and after blockade with 2-haloalkylamines, it was found that these agents produced an irreversible shift to the right in the dose-response curve without significant depression of the maximum response even at very high antagonist concentrations."( Irreversible blockade of responses to a partial agonist acting at the histamine H1-receptor.
Cook, D; Iwanow, D; Kenakin, T; Krueger, C, 1982
)
0.26
" Using modeled dose-response data both in their ideal form and with an added average deviation as well as previously published experimental data, a variety of analytical approaches were compared which differed in goodness-of-fit, ease of handling, and range of successful application."( Calculation of agonist efficacy, apparent affinity, and receptor population changes after administration of insurmountable antagonists: comparison of different analytical approaches.
Issaevitch, T; Woods, JH; Zernig, G, 1996
)
0.29
" The competitive alpha1-adrenoceptor antagonists produced dextral shifts of the dose-response curves to NA in longitudinal and circular muscle."( Discrimination by SZL49 between contractions evoked by noradrenaline in longitudinal and circular muscle of human vas deferens.
Amobi, NI; Guillebaud, J; Kaisary, AV; Smith, IC; Turner, E, 2002
)
0.31
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (570)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990556 (97.54)18.7374
1990's12 (2.11)18.2507
2000's2 (0.35)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 7.50

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index7.50 (24.57)
Research Supply Index6.41 (2.92)
Research Growth Index3.91 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (7.50)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews7 (1.15%)6.00%
Case Studies2 (0.33%)4.05%
Observational0 (0.00%)0.25%
Other600 (98.52%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]